All Title Author
Keywords Abstract

PLOS ONE  2013 

RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial

DOI: 10.1371/journal.pone.0081740

Full-Text   Cite this paper   Add to My Lib


Most women with estrogen receptor expressing breast cancers receiving anti-estrogens such as tamoxifen may not need or benefit from them. Besides the estrogen receptor, there are no predictive biomarkers to help select breast cancer patients for tamoxifen treatment. CCND1 (cyclin D1) gene amplification is a putative candidate tamoxifen predictive biomarker. The RSF1 (remodeling and spacing factor 1) gene is frequently co-amplified with CCND1 on chromosome 11q. We validated the predictive value of these biomarkers in the MA.12 randomized study of adjuvant tamoxifen vs. placebo in high-risk premenopausal early breast cancer. Premenopausal women with node-positive/high-risk node-negative early breast cancer received standard adjuvant chemotherapy and then were randomized to tamoxifen (20 mg/day) or placebo for 5 yrs. Overall survival (OS) and relapse-free survival (RFS) were evaluated. Fluorescent in-situ hybridization was performed on a tissue microarray of 495 breast tumors (74% of patients) to measure CCND1 and RSF1 copy number. A multivariate Cox model to obtain hazard ratios (HR) adjusting for clinico-pathologic factors was used to assess the effect of these biomarkers on Os and RFS. 672 women were followed for a median of 8.4 years. We were able to measure the DNA copy number of CCND1 in 442 patients and RSF1 in 413 patients. CCND1 gene amplification was observed in 8.7% and RSF1 in 6.8% of these patients, preferentially in estrogen receptor-positive breast cancers. No statistically significant interaction with treatment was observed for either CCND1 or RSF1 amplification, although patients with high RSF1 copy number did not show benefit from adjuvant tamoxifen (HR = 1.11, interaction p = 0.09). Unlike CCND1 amplification, RSF1 amplification may predict for outcome in high-risk premenopausal breast cancer patients treated with adjuvant tamoxifen.


[1]  Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J et al. (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364: 858-868. doi:10.1016/S0140-6736(04)16981-X. PubMed: 15351193.
[2]  Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, et al. (2010) A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12). Ann Oncol 21: 283-90.
[3]  Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541. doi:10.1016/j.ccr.2006.10.009. PubMed: 17157792.
[4]  Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL (2003) Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78: 323-335. doi:10.1023/A:1023033708204. PubMed: 12755491.
[5]  Stendahl M, Kronblad A, Rydén L, Emdin S, Bengtsson NO et al. (2004) Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90: 1942-1948. doi:10.1038/sj.bjc.6601831. PubMed: 15138475.
[6]  Bostner J, Waltersson MA, Fornander T, Skoog L, Nordenskj?ld B et al. (2007) Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26: 6997-7005. doi:10.1038/sj.onc.1210506. PubMed: 17486065.
[7]  Mao T-L, Hsu C-Y, Yen MJ, Gilks B, Sheu JJ-C et al. (2006) Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol 37: 1169-1175. doi:10.1016/j.humpath.2006.04.008. PubMed: 16938522.
[8]  Brown LA, Kalloger SE, Miller MA, Shih Ie M, McKinney SE, et al. (2008) Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 47: 481-9.
[9]  Hosein AN, Wu M, Arcand SL, Lavallée S, Hébert J et al. (2010) Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res 70: 5770-5777. doi:10.1158/1538-7445.AM10-5770. PubMed: 20570891.
[10]  Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC et al. (2007) American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145. PubMed: 17159189.
[11]  Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23: 9312-9318. doi:10.1200/JCO.2005.03.3266. PubMed: 16361630.
[12]  Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN et al. (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104: 452-460. doi:10.1093/jnci/djs126. PubMed: 22395643.
[13]  Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, et al. (2012) Breast International Group (BIG) 1-98 Collaborative Group: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J . Natl Cancer Inst 104: 441-51.
[14]  Reis-Filho JS, Savage K, Lambros M, James M, Steele D et al. (2006) Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 19: 999-1009. doi:10.1038/modpathol.3800621. PubMed: 16648863.
[15]  Lundgren K, Brown M, Pineda S, Cuzick J, Salter J et al. (2012) Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res 14: R57. doi:10.1186/bcr3160. PubMed: 22475046.
[16]  Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ et al. (2005) Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A 102: 14004-14009. doi:10.1073/pnas.0504195102. PubMed: 16172393. Available online at: doi:10.1073/pnas.0504195102. Available online at: PubMed: 16172393.
[17]  Loyola A, Huang JY, LeRoy G, Hu S, Wang YH et al. (2003) Functional analysis of the subunits of the chromatin assembly factor RSF. Mol Cell Biol 23: 6759-6768. doi:10.1128/MCB.23.19.6759-6768.2003. PubMed: 12972596.
[18]  LeRoy G, Orphanides G, Lane WS, Reinberg D (1998) Requirement of RSF and FACT for transcription of chromatin templates in vitro. Science 282: 1900-1904. doi:10.1126/science.282.5395.1900. PubMed: 9836642.
[19]  Vicent GP, Nacht AS, Zaurín R, Ballaré C, Clausell J et al. (2010) Minireview: role of kinases and chromatin remodeling in progesterone signaling to chromatin. Mol Endocrinol 24: 2088-2098. doi:10.1210/me.2010-0027. PubMed: 20484412.


comments powered by Disqus

Contact Us


微信:OALib Journal